Journal article
Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer
Gynecologic Oncology Reports, Vol.20(C), pp.103-104
05/2017
DOI: 10.1016/j.gore.2017.03.011
PMCID: PMC5377914
PMID: 28393095
Abstract
Few advances in the treatment of advanced epithelial ovarian cancer have improved patient overall survival. However, the incorporation of intraperitoneal administration of platinum based chemotherapy to standard treatment was one such advancement. It is understood that the intraperitoneal regimen is associated with increased toxicity when compared to intravenous administration alone; however, information regarding the specific risk of ototoxicity is lacking in the literature. We report a case of almost complete sensorineural hearing loss after one cycle of intraperitoneal cisplatin. Three days after receiving an intravenous 24h paclitaxel at 135mg/m2 and subsequent intraperitoneal infusion of cisplatin at 75mg/m2, the patient presented with profound bilateral sensorineural hearing loss. The patient experienced no recovery of hearing despite an aggressive systemic steroid taper and change in chemotherapy regimen to alternative agents. She is currently under consideration for cochlear device implantation. Generally, cisplatin related ototoxicity during treatment of epithelial ovarian cancer is gradual, limited to high-frequency ranges and dose-related; however, the toxicity with only one standard dose can be profound and irreversible. This risk should be addressed when counseling patients prior to initiation of treatment. •Cisplatin induced ototoxicity can be severe and irreversible after just one dose.•The mainstay of treatment remains early recognition and treatment modification.•Counseling regarding cisplatin induced ototoxicity should be included in the consent process.
Details
- Title: Subtitle
- Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer
- Creators
- Megan E McDonald - Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, IA, United StatesJordan Mattson - Department of Obstetrics and Gynecology, The University of Iowa Hospitals and Clinics, Iowa City, IA, United StatesEmily Hill - Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, IA, United States
- Resource Type
- Journal article
- Publication Details
- Gynecologic Oncology Reports, Vol.20(C), pp.103-104
- DOI
- 10.1016/j.gore.2017.03.011
- PMID
- 28393095
- PMCID
- PMC5377914
- NLM abbreviation
- Gynecol Oncol Rep
- ISSN
- 2352-5789
- eISSN
- 2352-5789
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 05/2017
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9983931576502771
Metrics
18 Record Views